Literature DB >> 16854582

Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells.

Yi-Wen Huang1, Li-Shu Wang, Hsiang-Lin Chang, Weiping Ye, Sherry Shu, Yasuro Sugimoto, Young C Lin.   

Abstract

In normal prostate, keratinocyte growth factor (KGF), also known as fibroblast growth factor-7 (FGF-7) serves as a paracrine growth factor synthesized in stromal cells that acts on epithelial cells through its receptor, KGFR. KGF and KGFR were found in human cancer epithelial cells as well as stromal cells. Since KGF expressed in epithelial cells of benign prostatic hyperplasia (BPH) and in prostate cancer, it has been suggested that KGF might act as an autocrine factor in BPH and prostate cancer. To investigate the roles of KGF in cancerous stroma, primary cultured human prostate cancer stromal cells (PCSCs) were isolated and evaluated. These PCSCs possessed estrogen receptors and KGFR, but not androgen receptor as determined by RT-PCR and Western blot, respectively. KGF exhibited mitogenic and anti-apoptotic effects that correlated with induction of cyclin-D1, Bcl-2, Bcl-xL and phospho-Akt expression in PCSCs, where treatment with KGF antiserum abolished cell proliferation and anti-apoptotic protein expression. PCSCs exposed to KGF for various time periods resulted in phosphorylation of Akt and subsequent up-regulation of Bcl-2. KGF modulated dynamic protein expression indicated that KGF triggered cell cycle machinery and then activated anti-apoptotic actions in PCSCs. Cell proliferation analysis indicated that tamoxifen or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression. In summary, KGF has an autocrine effect and serves as a survival factor in primary cultured human prostate cancer stromal cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16854582     DOI: 10.1016/j.jsbmb.2006.03.005

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

1.  Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.

Authors:  Rajeev Kumar; Vikas Verma; Amit Sarswat; J P Maikhuri; Ashish Jain; Rajeev K Jain; V L Sharma; Diwakar Dalela; Gopal Gupta
Journal:  Invest New Drugs       Date:  2010-12-23       Impact factor: 3.850

Review 2.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

3.  Expression of keratinocyte growth factor and its receptor in rat tracheal cartilage: possible involvement in wound healing of the damaged cartilage.

Authors:  Takafumi Abo; Takeshi Nagayasu; Yoshitaka Hishikawa; Tsutomu Tagawa; Atsushi Nanashima; Takatomo Yamayoshi; Keitaro Matsumoto; Shucai An; Takehiko Koji
Journal:  Acta Histochem Cytochem       Date:  2010-04-26       Impact factor: 1.938

Review 4.  Growth factors in benign prostatic hyperplasia: basic science implications.

Authors:  M Scott Lucia; James R Lambert
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 5.  Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions.

Authors:  Mohamed Ben-Eltriki; Subrata Deb; Emma S Tomlinson Guns
Journal:  J Cancer       Date:  2016-01-15       Impact factor: 4.207

6.  FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.

Authors:  Christopher I Milton; Joanna Selfe; Ewa Aladowicz; Stella Y K Man; Carolina Bernauer; Edoardo Missiaglia; Zoë S Walters; Susanne A Gatz; Anna Kelsey; Melanie Generali; Gary Box; Melanie Valenti; Alexis de Haven-Brandon; David Galiwango; Angela Hayes; Matthew Clarke; Elisa Izquierdo; David Gonzalez De Castro; Florence I Raynaud; Vladimir Kirkin; Janet M Shipley
Journal:  Mol Oncol       Date:  2021-12-18       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.